文献速递主动脉疾病

基于EVAS FORWARD IDE试验2年结果优化Nellix系统腔内动脉瘤封堵的解剖学适应证

Refinement of anatomic indications for the Nellix System for endovascular aneurysm sealing based on 2-year outcomes from the EVAS FORWARD IDE trial.
PubMed 文献 · J Vasc Surg · 2018-03-31

该研究基于EVAS FORWARD IDE关键试验2年结果,通过工程评估、统计分析和临床评估,识别出Nellix系统腔内动脉瘤封堵术后移位的风险因素为小主动脉流腔相对大瘤内血栓负荷及大主动脉颈直径,据此修订使用说明(IFU),排除血栓指数>1.4、主动脉颈直径>28 mm及主动脉颈锥度(肾下颈直径变化>10%)的患者,并要求髂动脉远端锚定区10 mm。按修订标准分层回顾性分析显示,符合IFU组2年无移位率97.7% vs 不符合IFU组93.2%(P=0.0125),复合无移位、IA型内漏或瘤体扩张率95.9% vs 85.1%(P=0.0017)。

要点

  • 修订IFU排除血栓指数>1.4、颈直径>28 mm及颈锥度>10%的患者。
  • 符合IFU组2年无移位率97.7% vs 不符合IFU组93.2%(P=0.0125)。
  • 复合无移位、IA型内漏或瘤体扩张率符合IFU组95.9% vs 不符合IFU组85.1%(P=0.0017)。

核心结论

  • 随时间推移EVAS失败模式的呈现不可避免;通过详细影像及工程和统计分析,理解了EVAS特异性不良事件的风险因素并定义了最适合Nellix的患者。
  • 采用EVAS特异性IFU定义方法,符合IFU的患者被识别为那些大动脉瘤伴少量血栓、传统装置易发生II型内漏和瘤囊扩张的患者;接受Nellix治疗时,这些患者预计可获得优异结果,尤其是低复合内漏率和低全因死亡率。

研究设计与样本

  • 基于EVAS FORWARD IDE关键试验的2年结果分析,纳入关键试验患者(N=150)、roll-in队列(N=29)和持续准入项目(N=154)。
  • 所有队列患者入组时均符合当时IFU;采用逻辑回归模型支持移位机制分析。
  • 根据修订的形态学标准对患者结局进行分层并回顾性分析。

主要发现

  • 2年全因死亡无事件率为94%。
  • 2年复合内漏无事件率:符合IFU组95% vs 不符合IFU组92%。
  • 2年无移位率:符合IFU组97.7% vs 不符合IFU组93.2%(P=0.0125)。
  • 2年无动脉瘤扩大率:符合IFU组98.1% vs 不符合IFU组93.5%(P值不可得,因log-rank检验假设不满足)。
  • 复合无移位、IA型内漏或动脉瘤扩张率:符合IFU组95.9% vs 不符合IFU组85.1%(P=0.0017)。

关键数值与推荐

  • 修订IFU排除血栓指数(最大瘤囊/最大流腔直径)>1.4的患者。
  • 修订IFU排除主动脉颈直径>28 mm的患者。
  • 修订IFU排除主动脉颈锥度(肾下颈直径变化>10%)的患者。
  • 修订IFU要求髂动脉远端锚定区10 mm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Nellix System (Endologix, Inc, Irvine, Calif) for endovascular aneurysm sealing (EVAS) is a novel approach to abdominal aortic aneurysm treatment and conceptually different from endovascular aneurysm repair, whereby polymer is employed to fill and actively manage the abdominal aortic aneurysm sac. One-year safety and effectiveness results of the Nellix pivotal trial demonstrated encouraging outcomes with very low morbidity and mortality and high procedural and treatment success. Two-year imaging revealed a signal of migration, leading to a field safety notification issued by the manufacturer on October 21, 2016, and a dedicated root cause analysis, resulting in refinements to the instructions for use (IFU). We report the 2-year results of the investigational device exemption pivotal trial stratified according to the new and original criteria for selection of patients. METHODS: Comprehensive engineering evaluations, statistical analyses, and clinical assessments were conducted looking at patients enrolled in the pivotal trial (N = 150), roll-in cohort (N = 29), and continued access program (N = 154). All patients in all cohorts were treated on-IFU at the time of enrollment. Logistic regression models supported the mechanism that migration with Nellix is associated with a small aortic flow lumen relative to a large aneurysm thrombus burden and large aortic neck diameters. Based on these findings, refinements to the IFU criteria were applied, excluding patients with a thrombus index (maximum aneurysm sac/maximum flow lumen diameter) >1.4, aortic neck diameter >28 mm, and aortic neck conicity (>10% diameter change along the infrarenal neck) and requiring a 10-mm distal seal zone in the iliac artery. RESULTS: Freedom from all-cause mortality at 2 years was 94%. Patient outcomes were then stratified on the refined morphologic criteria and analyzed retrospectively. Two-year freedom from composite endoleak was high among both cohorts (95% on-IFU vs 92% off-IFU). Freedom from migration was 97.7% on-IFU vs 93.2% off-IFU (P = .0125). Freedom from aneurysm enlargement was 98.1% on-IFU vs 93.5% off-IFU (P value is not available because of failure of log-rank test assumptions). Composite freedom from migration, type IA endoleak, or aneurysm expansion was 95.9% among the on-IFU cohort vs 85.1% in the off-IFU cohort (P = .0017). CONCLUSIONS: Consistent with the introduction of a novel therapy, the presentation of failure modes of EVAS over time was inevitable. Using detailed imaging as well as engineering and statistical analysis, we were able to understand risk factors for adverse events specific to EVAS and defined those patients best suited for Nellix. With this EVAS-specific approach to defining IFU, on-IFU patients were identified as those with large aneurysms with little thrombus that would be prone to type II endoleaks and sac expansion with traditional devices. When treated with Nellix, these patients were predicted to experience exceptional results, especially with regard to a low composite endoleak rate and low all-cause mortality.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Carpenter JP, Lane JS, Trani J, et al. Refinement of anatomic indications for the Nellix System for endovascular aneurysm sealing based on 2-year outcomes from the EVAS FORWARD IDE trial. J Vasc Surg. 2018. PMID: 29609994. doi:10.1016/j.jvs.2018.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。